JP7039081B1 - Anti-allergen agent and anti-allergen performance imparting method - Google Patents
Anti-allergen agent and anti-allergen performance imparting method Download PDFInfo
- Publication number
- JP7039081B1 JP7039081B1 JP2021117474A JP2021117474A JP7039081B1 JP 7039081 B1 JP7039081 B1 JP 7039081B1 JP 2021117474 A JP2021117474 A JP 2021117474A JP 2021117474 A JP2021117474 A JP 2021117474A JP 7039081 B1 JP7039081 B1 JP 7039081B1
- Authority
- JP
- Japan
- Prior art keywords
- allergen
- agent
- compound
- mass
- allergen agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 252
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 132
- 238000000034 method Methods 0.000 title claims description 20
- -1 silicic acid compound Chemical class 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- JUWGUJSXVOBPHP-UHFFFAOYSA-B titanium(4+);tetraphosphate Chemical compound [Ti+4].[Ti+4].[Ti+4].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JUWGUJSXVOBPHP-UHFFFAOYSA-B 0.000 claims abstract description 27
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 17
- 239000005749 Copper compound Substances 0.000 claims description 15
- 150000001880 copper compounds Chemical class 0.000 claims description 15
- 229940100890 silver compound Drugs 0.000 claims description 15
- 150000003379 silver compounds Chemical class 0.000 claims description 15
- 239000010936 titanium Substances 0.000 claims description 12
- 240000005109 Cryptomeria japonica Species 0.000 claims description 10
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 10
- 241000218691 Cupressaceae Species 0.000 claims description 7
- 241000238876 Acari Species 0.000 claims description 5
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims description 5
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 3
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 claims description 2
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000005751 Copper oxide Substances 0.000 claims description 2
- 229910021612 Silver iodide Inorganic materials 0.000 claims description 2
- 229910052946 acanthite Inorganic materials 0.000 claims description 2
- 229910000431 copper oxide Inorganic materials 0.000 claims description 2
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 claims description 2
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 claims description 2
- 229940045105 silver iodide Drugs 0.000 claims description 2
- 229910001923 silver oxide Inorganic materials 0.000 claims description 2
- 229940056910 silver sulfide Drugs 0.000 claims description 2
- XUARKZBEFFVFRG-UHFFFAOYSA-N silver sulfide Chemical compound [S-2].[Ag+].[Ag+] XUARKZBEFFVFRG-UHFFFAOYSA-N 0.000 claims description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims 1
- 229910052919 magnesium silicate Inorganic materials 0.000 claims 1
- 235000019792 magnesium silicate Nutrition 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000005259 measurement Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241001091433 Itea Species 0.000 description 8
- 239000013573 pollen allergen Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000003118 sandwich ELISA Methods 0.000 description 8
- 239000000178 monomer Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 6
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 241000218645 Cedrus Species 0.000 description 4
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 description 4
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000004115 Sodium Silicate Substances 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 235000021120 animal protein Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 229910052911 sodium silicate Inorganic materials 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229920006280 packaging film Polymers 0.000 description 1
- 239000012785 packaging film Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229910000048 titanium hydride Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
【課題】アレルゲンを不活性化し得る新規な抗アレルゲン剤を提供する。【解決手段】リン酸チタニウム系化合物を含む、抗アレルゲン剤。ケイ酸化合物をさらに含むことが好ましい。【選択図】なしPROBLEM TO BE SOLVED: To provide a novel anti-allergen agent capable of inactivating an allergen. An anti-allergen agent containing a titanium phosphate-based compound. It is preferable to further contain a silicic acid compound. [Selection diagram] None
Description
本発明は、抗アレルゲン剤及び抗アレルゲン性能付与方法に関する。 The present invention relates to an anti-allergen agent and a method for imparting anti-allergen performance.
従来、スギ花粉やヒノキ花粉などの植物性蛋白、ダニ虫体やその排泄物などの動物性蛋白などのアレルゲンを継続的に吸入、接触、摂取することにより感作状態となる、アレルギー性疾患が問題となっている。 Conventionally, allergic diseases that become sensitized by continuously inhaling, contacting, and ingesting plant proteins such as cedar pollen and hinoki pollen, and animal proteins such as ticks and their excrement. It's a problem.
アレルギー性疾患の発症防止や症状低減のためには、アレルギー性疾患の原因となるアレルゲンを室内空間から除去又は不活化することが重要である。 In order to prevent the onset of allergic diseases and reduce symptoms, it is important to remove or inactivate allergens that cause allergic diseases from the indoor space.
例えば、特許文献１には、タンニン酸を有効成分とする抗アレルゲン剤組成物を、繊維製品等の対象物に付着させることにより、アレルゲンを不活性化させる技術が開示されている。 For example, Patent Document 1 discloses a technique for inactivating an allergen by adhering an anti-allergen agent composition containing tannic acid as an active ingredient to an object such as a textile product.
本発明は、アレルゲンを不活性化し得る新規な抗アレルゲン剤を提供することを主な目的とする。さらに、本発明は、当該抗アレルゲン剤を利用した抗アレルゲン性能付与方法を提供することをも目的とする。 An object of the present invention is to provide a novel anti-allergen agent capable of inactivating an allergen. Furthermore, it is also an object of the present invention to provide a method for imparting anti-allergen performance using the anti-allergen agent.
本発明の発明者らは、前記課題を解決すべく、鋭意検討を行った。その結果、リン酸チタニウム系化合物を有効成分として利用することにより、植物性蛋白、動物性蛋白などのアレルゲンを好適に低減できることを見出した。 The inventors of the present invention have made diligent studies to solve the above problems. As a result, it was found that allergens such as plant-based protein and animal protein can be suitably reduced by using a titanium phosphate-based compound as an active ingredient.
本発明は、このような知見に基づき、さらに検討を重ねることにより完成したものである。即ち、本開示は、下記に掲げる態様の発明を提供する。
項１． リン酸チタニウム系化合物を含む、抗アレルゲン剤。
項２． ケイ酸化合物をさらに含む、項１に記載の抗アレルゲン剤。
項３． 銀化合物及び銅化合物のうち少なくとも一方をさらに含む、項１または２に記載の抗アレルゲン剤。
項４． 前記リン酸チタニウム系化合物は、下記一般式で表される化合物及び／又はその縮合物である、項１～３のいずれか１項に記載の抗アレルゲン剤。
Ｔｉ（ＯＨ）x（ＰＯ4）y（ＨＰＯ4）z（Ｈ2ＰＯ4）l（ＯＲ）m
（Ｒは炭素数１～４のアルキル基を示し、ｘは０～３の整数であり、ｙは０～４の整数であり、ｚは０～４の整数であり、ｌは０～４の整数であり、ｍは０～３の整数であり、ｘ＋３ｙ＋２ｚ＋ｌ＋ｍ＝４であり、ｙ＋ｚ＋１≧１である。）
項５． スギ花粉由来のアレルゲン、ヒノキ花粉由来のアレルゲン及びダニ由来のアレルゲンからなる群より選択される少なくとも１種のアレルゲンに対する抗アレルゲン剤である、項１～４のいずれか１項に記載の抗アレルゲン剤。
項６． 対象物に抗アレルゲン性能を付与する方法であって、
項１～５のいずれか１項に記載の抗アレルゲン剤を、前記対象物の表面に付着させる、抗アレルゲン性能付与方法。
項７． 前記抗アレルゲン剤を前記対象物に噴霧することで、前記対象物の表面に前記抗アレルゲン剤を付着させる、項６に記載の抗アレルゲン性能付与方法。
The present invention has been completed by further studies based on such findings. That is, the present disclosure provides the inventions of the following aspects.
Item 1. An anti-allergen agent containing a titanium phosphate-based compound.
Item 2. Item 2. The anti-allergen agent according to Item 1, further comprising a silicic acid compound.
Item 3. Item 2. The antiallergen agent according to Item 1 or 2, further comprising at least one of a silver compound and a copper compound.
Item 4. Item 6. The anti-allergen agent according to any one of Items 1 to 3, wherein the titanium phosphate-based compound is a compound represented by the following general formula and / or a condensate thereof.
Ti (OH) x (PO 4 ) y (HPO 4 ) z (H 2 PO 4 ) l (OR) m
(R represents an alkyl group having 1 to 4 carbon atoms, x is an integer of 0 to 3, y is an integer of 0 to 4, z is an integer of 0 to 4, and l is an integer of 0 to 4. It is an integer, m is an integer of 0 to 3, x + 3y + 2z + l + m = 4, and y + z + 1 ≧ 1.)
Item 5. Item 2. The anti-allergen agent according to any one of Items 1 to 4, which is an anti-allergen agent against at least one allergen selected from the group consisting of allergens derived from sugi pollen, allergens derived from cypress pollen and allergens derived from ticks. ..
Item 6. A method of imparting anti-allergen performance to an object,
A method for imparting anti-allergen performance, wherein the anti-allergen agent according to any one of Items 1 to 5 is attached to the surface of the object.
Item 7. Item 6. The method for imparting anti-allergen performance according to Item 6, wherein the anti-allergen agent is adhered to the surface of the object by spraying the anti-allergen agent onto the object.
本発明によれば、アレルゲンを不活性化し得る新規な抗アレルゲン剤を提供することができる。また、当該抗アレルゲン剤を利用した抗アレルゲン性能付与方法を提供することもできる。 According to the present invention, it is possible to provide a novel anti-allergen agent capable of inactivating the allergen. It is also possible to provide a method for imparting anti-allergen performance using the anti-allergen agent.
本発明の抗アレルゲン剤は、リン酸チタニウム系化合物を含むことを特徴とする。本発明においては、抗アレルゲン剤がリン酸チタニウム系化合物を含むことにより、植物性蛋白、動物性蛋白などのアレルゲンを不活性化し得る。以下、本発明の抗アレルゲン剤及びこれを利用した抗アレルゲン性能付与方法について詳述する。 The anti-allergen agent of the present invention is characterized by containing a titanium phosphate-based compound. In the present invention, the anti-allergen agent may inactivate allergens such as plant-based protein and animal protein by containing a titanium phosphate-based compound. Hereinafter, the anti-allergen agent of the present invention and the method for imparting anti-allergen performance using the same will be described in detail.
なお、本明細書において、「含む」とは、「本質的にからなる」と、「からなる」をも包含する。また、本明細書において、「～」で結ばれた数値は、「～」の前後の数値を下限値及び上限値として含む数値範囲を意味する。複数の下限値と複数の上限値が別個に記載されている場合、任意の下限値と上限値を選択し、「～」で結ぶことができるものとする。 In addition, in this specification, "including" also includes "consisting of" and "consisting of". Further, in the present specification, the numerical value connected by "-" means a numerical range including the numerical values before and after "-" as the lower limit value and the upper limit value. When multiple lower limit values and multiple upper limit values are described separately, any lower limit value and upper limit value can be selected and connected by "~".
本発明の抗アレルゲン剤は、リン酸チタニウム系化合物を含む。リン酸チタニウム系化合物は、具体的には、一般式：Ｔｉ（ＯＨ）x（ＰＯ4）y（ＨＰＯ4）z（Ｈ2ＰＯ4）l（ＯＲ）m（ここで、Ｒは炭素数１～４のアルキル基を示し、エチル基またはイソプロピル基が好ましい。ｘは０～３の整数であり、ｙは０～４の整数であり、ｚは０～４の整数であり、ｌは０～４の整数であり、ｍは０～３の整数であり、ｘ＋３ｙ＋２ｚ＋ｌ＋ｍ＝４であり、ｙ＋ｚ＋１≧１である。）の化学組成又はこれが縮合した化学組成であることが好ましい。すなわち、リン酸チタニウム系化合物は、前記一般式で表されるリン酸チタニウム系化合物（単量体）であってもよいし、当該化合物の縮合物（縮合体）であってもよい。 The anti-allergen agent of the present invention contains a titanium phosphate-based compound. Specifically, the titanium phosphate-based compound has a general formula: Ti (OH) x (PO 4 ) y (HPO 4 ) z (H 2 PO 4 ) l (OR) m (where R has 1 carbon atom). It indicates an alkyl group of ~ 4, preferably an ethyl group or an isopropyl group. X is an integer of 0 to 3, y is an integer of 0 to 4, z is an integer of 0 to 4, and l is an integer of 0 to 4. It is an integer of 4, m is an integer of 0 to 3, x + 3y + 2z + l + m = 4, and y + z + 1 ≧ 1), or a condensed chemical composition thereof is preferable. That is, the titanium phosphate-based compound may be a titanium phosphate-based compound (monomer) represented by the above general formula, or may be a condensate (condensate) of the compound.
リン酸チタニウム系化合物（単量体）の具体例としては、Ｔｉ（ＯＨ）（Ｈ2ＰＯ4）2（ＯＲ）、Ｔｉ（ＯＨ）（ＰＯ4）、Ｔｉ（ＯＨ）2（Ｈ2ＰＯ4）（ＯＲ）、Ｔｉ（ＯＨ）（ＨＰＯ4）（ＯＲ）、Ｔｉ（ＯＨ）（ＨＰＯ4）（Ｈ2ＰＯ4）、Ｔｉ（ＯＨ）2（Ｈ2ＰＯ4）2、Ｔｉ（ＯＨ）3（Ｈ2ＰＯ4）、Ｔｉ（ＯＨ）3（ＯＲ）などが挙げられる。ここで、Ｒは前記と同じである。 Specific examples of the titanium hydride compound (monomer) include Ti (OH) (H 2 PO 4 ) 2 (OR), Ti (OH) (PO 4 ), Ti (OH) 2 (H 2 PO 4 ). ) (OR), Ti (OH) (HPO 4 ) (OR), Ti (OH) (HPO 4 ) (H 2 PO 4 ), Ti (OH) 2 (H 2 PO 4 ) 2 , Ti (OH) 3 (H 2 PO 4 ), Ti (OH) 3 (OR) and the like can be mentioned. Here, R is the same as described above.
前記一般式で表されるリン酸チタニウム系化合物（単量体）が結合した縮合物は、本発明の効果を奏することを限度として、特に限定はされず、例えば、前記一般式で表されるリン酸チタニウム系化合物が２～１０分子程度縮合した化合物が好ましい。縮合形式については、特に制限されず、例えば、前記一般式で表されるリン酸チタニウム系化合物から、水分子が脱離して得られる縮合形式が挙げられる。 The condensate to which the titanium phosphate-based compound (monomer) represented by the general formula is bound is not particularly limited as long as the effect of the present invention is exhibited, and is represented by the general formula, for example. A compound in which about 2 to 10 molecules of a titanium phosphate compound is condensed is preferable. The condensation form is not particularly limited, and examples thereof include a condensation form obtained by desorbing water molecules from a titanium phosphate-based compound represented by the above general formula.
本発明の抗アレルゲン剤に含まれるリン酸チタニウム系化合物は、１種類のみであってもよいし、２種類以上であってもよい。また、リン酸チタニウム系化合物の縮合物は、１種類のリン酸チタニウム系化合物（単量体）の縮合物であってもよいし、２種類以上のリン酸チタニウム系化合物（単量体）の縮合物であってもよい。 The titanium phosphate-based compound contained in the anti-allergen agent of the present invention may be only one kind or two or more kinds. Further, the condensate of the titanium phosphate compound may be a condensate of one kind of titanium phosphate compound (monomer), or may be a condensate of two or more kinds of titanium phosphate compounds (monomer). It may be a condensate.
リン酸チタニウム系化合物（単量体または縮合体）の製造方法については、例えば、特許３８２９６４０号や特許４４３０８７７号に記載の方法を採用することができる。具体例としては、四塩化チタンの加水分解物とリン酸とを反応させることによって、リン酸チタニウム系化合物が得られる。すなわち、リン酸チタニウム系化合物は、四塩化チタン加水分解物のリン酸化物（Ｐｈｏｓｐｈｏｒｙｌａｔｉｏｎ ｏｆ ｔｉｔａｎｉｕｍ ｔｅｔｒａｃｈｌｏｒｉｄｅ ｈｙｄｒｏｌｙｚａｔｅ）ということもできる。 As a method for producing a titanium phosphate-based compound (monomer or condensate), for example, the methods described in Japanese Patent No. 389640 and Japanese Patent No. 4430877 can be adopted. As a specific example, a titanium phosphate-based compound can be obtained by reacting a hydrolyzate of titanium tetrachloride with phosphoric acid. That is, the titanium phosphate-based compound can also be referred to as a phosphorylation of titanium tetrachloride dehydrate of a titanium tetrachloride hydrolyzate.
本発明の抗アレルゲン剤において、リン酸チタニウム系化合物の含有率については、本発明の効果を奏すれば特に制限はなく、例えば０．０００５質量％以上、好ましくは０．００５質量％以上、さらに好ましくは０．０５質量％以上、さらに好ましくは０．１質量％以上である。なお、リン酸チタニウム系化合物の含有率の上限については、特に制限はなく、例えば、１０質量％以下、５質量％以下、２．５質量％以下などが挙げられる。 In the anti-allergen agent of the present invention, the content of the titanium phosphate compound is not particularly limited as long as the effect of the present invention is exhibited, for example, 0.0005% by mass or more, preferably 0.005% by mass or more, and further. It is preferably 0.05% by mass or more, more preferably 0.1% by mass or more. The upper limit of the content of the titanium phosphate compound is not particularly limited, and examples thereof include 10% by mass or less, 5% by mass or less, and 2.5% by mass or less.
なお、後述の通り、本発明の抗アレルゲン剤を利用した抗アレルゲン性能付与方法において、本発明の抗アレルゲン剤は、これを製造・保管・流通させる際には原液の形態とし、用時に水等の液性媒体で希釈して抗アレルゲン剤とし、対象物に付着させて抗アレルゲン性能を付与することもできる。本発明の抗アレルゲン剤の原液において、リン酸チタニウム系化合物の含有率については、水等の液性媒体で希釈して本発明の抗アレルゲン剤を調製できれば特に制限されず、例えば、例えば０．０５質量％以上、好ましくは０．５質量％以上、さらに好ましくは５質量％以上、さらに好ましくは１０質量％以上である。なお、原液におけるリン酸チタニウム系化合物の含有率の上限については、特に制限はなく、例えば、２０質量％以下、１０質量％以下、５質量％以下などが挙げられる。 As will be described later, in the method for imparting anti-allergen performance using the anti-allergen agent of the present invention, the anti-allergen agent of the present invention is in the form of a stock solution when it is manufactured, stored and distributed, and water or the like is used. It is also possible to dilute it with a liquid medium to make it an anti-allergen agent and attach it to an object to impart anti-allergen performance. The content of the titanium phosphate compound in the stock solution of the anti-allergen agent of the present invention is not particularly limited as long as it can be diluted with a liquid medium such as water to prepare the anti-allergen agent of the present invention. It is 05% by mass or more, preferably 0.5% by mass or more, more preferably 5% by mass or more, still more preferably 10% by mass or more. The upper limit of the content of the titanium phosphate compound in the undiluted solution is not particularly limited, and examples thereof include 20% by mass or less, 10% by mass or less, and 5% by mass or less.
本発明の効果をより一層好適に発揮する観点から、本発明の抗アレルゲン剤は、リン酸チタニウム系化合物に加えて、ケイ酸化合物をさらに含むことが好ましい。 From the viewpoint of more preferably exerting the effects of the present invention, the anti-allergen agent of the present invention preferably further contains a silicic acid compound in addition to the titanium phosphate-based compound.
ケイ酸化合物は、一般式：［ＳｉＯx（ＯＨ）4-2x］nで表される化合物又はその塩であることが好ましい。当該一般式において、ｘ及びｎは、任意の正の数である。ケイ酸化合物の具体例としては、オルトケイ酸、メタケイ酸、メタ二ケイ酸、またはこれらのうち少なくとも１種の多量体が挙げられる。ケイ酸化合物は、塩の形態で本発明の抗アレルゲン剤に含まれていてもよい。ケイ酸化合物の中でも、水への溶解度が高いことから、メタケイ酸ナトリウムであることが好ましい。本発明の抗アレルゲン剤に含まれるケイ酸化合物は、１種類のみであってもよいし、２種類以上であってもよい。 The silicic acid compound is preferably a compound represented by the general formula: [SiO x (OH) 4-2x ] n or a salt thereof. In the general formula, x and n are arbitrary positive numbers. Specific examples of the silicic acid compound include orthosilicic acid, metasilicic acid, metasilicic acid, or a multimer of at least one of these. The silicic acid compound may be contained in the anti-allergen agent of the present invention in the form of a salt. Among the silicic acid compounds, sodium metasilicate is preferable because it has high solubility in water. The silicic acid compound contained in the anti-allergen agent of the present invention may be only one kind or two or more kinds.
本発明の抗アレルゲン剤において、ケイ酸化合物の割合は、リン酸チタニウム系化合物を１００質量部として、好ましくは０～２５０質量部、より好ましくは１０～１５０質量部、さらに好ましくは５０～１００質量部である。 In the anti-allergen agent of the present invention, the ratio of the silicic acid compound is 100 parts by mass, preferably 0 to 250 parts by mass, more preferably 10 to 150 parts by mass, still more preferably 50 to 100 parts by mass, based on the titanium phosphate compound. It is a department.
本発明の抗アレルゲン剤において、ケイ酸化合物の含有率については、本発明の効果を奏すれば特に制限はなく、例えば０．０００１質量％以上、好ましくは０．００１質量％以上、さらに好ましくは０．０１質量％以上、さらに好ましくは０．１質量％以上である。なお、ケイ酸化合物の含有率の上限については、特に制限はなく、例えば、０．８質量％以下、０．６質量％以下、０．４質量％以下などが挙げられる。 In the anti-allergen agent of the present invention, the content of the silicic acid compound is not particularly limited as long as the effect of the present invention is exhibited, for example, 0.0001% by mass or more, preferably 0.001% by mass or more, more preferably 0.001% by mass or more. It is 0.01% by mass or more, more preferably 0.1% by mass or more. The upper limit of the content of the silicic acid compound is not particularly limited, and examples thereof include 0.8% by mass or less, 0.6% by mass or less, and 0.4% by mass or less.
また、本発明の抗アレルゲン剤の原液において、ケイ酸化合物の含有率については、水等の液性媒体で希釈して本発明の抗アレルゲン剤を調製できれば特に制限されず、例えば、例えば０．０１質量％以上、好ましくは０．１質量％以上、さらに好ましくは１質量％以上、さらに好ましくは１０質量％以上である。なお、原液におけるケイ酸化合物の含有率の上限については、特に制限はなく、例えば、２５質量％以下、２０質量％以下、１５質量％以下などが挙げられる。 Further, in the stock solution of the anti-allergen agent of the present invention, the content of the silicic acid compound is not particularly limited as long as it can be diluted with a liquid medium such as water to prepare the anti-allergen agent of the present invention. It is 01% by mass or more, preferably 0.1% by mass or more, more preferably 1% by mass or more, still more preferably 10% by mass or more. The upper limit of the content of the silicic acid compound in the undiluted solution is not particularly limited, and examples thereof include 25% by mass or less, 20% by mass or less, and 15% by mass or less.
本発明の効果をより一層好適に発揮する観点から、本発明の抗アレルゲン剤は、リン酸チタニウム系化合物に加えて、銀化合物及び銅化合物のうち少なくとも一方をさらに含むことが好ましい。また、本発明の抗アレルゲン剤は、リン酸チタニウム系化合物及びケイ酸化合物に加えて、銀化合物及び銅化合物のうち少なくとも一方をさらに含むことがより好ましい。 From the viewpoint of more preferably exerting the effects of the present invention, the anti-allergen agent of the present invention preferably further contains at least one of a silver compound and a copper compound in addition to the titanium phosphate-based compound. Further, it is more preferable that the anti-allergen agent of the present invention further contains at least one of a silver compound and a copper compound in addition to the titanium phosphate compound and the silicic acid compound.
銀化合物としては、本発明の効果を奏することを限度として、特に制限されず、具体例としては、硝酸銀、酸化銀、硫化銀、臭化銀、ヨウ化銀などが挙げられる。これらの中でも、水への溶解度が高いことから、硝酸銀が好ましい。本発明の抗アレルゲン剤に含まれる銀化合物は、１種類のみであってもよいし、２種類以上であってもよい。 The silver compound is not particularly limited as long as the effect of the present invention is exhibited, and specific examples thereof include silver nitrate, silver oxide, silver sulfide, silver bromide, and silver iodide. Among these, silver nitrate is preferable because of its high solubility in water. The silver compound contained in the anti-allergen agent of the present invention may be only one kind or two or more kinds.
本発明の抗アレルゲン剤において、銀化合物の割合は、リン酸チタニウム系化合物を１００質量部として、好ましくは０～５００質量部、より好ましくは５０～４００質量部、さらに好ましくは７５～３００質量部である。 In the anti-allergen agent of the present invention, the ratio of the silver compound is preferably 0 to 500 parts by mass, more preferably 50 to 400 parts by mass, still more preferably 75 to 300 parts by mass, with the titanium phosphate compound as 100 parts by mass. Is.
本発明の抗アレルゲン剤において、銀化合物の含有率については、本発明の効果を奏すれば特に制限はなく、例えば０．００００５質量％以上、好ましくは０．０００５質量％以上、さらに好ましくは０．００５質量％以上、さらに好ましくは０．０１質量％以上である。なお、銀化合物の含有率の上限については、特に制限はなく、例えば、０．２質量％以下、０．１質量％以下、０．０５質量％以下などが挙げられる。 In the anti-allergen agent of the present invention, the content of the silver compound is not particularly limited as long as the effect of the present invention is exhibited, for example, 0.00005% by mass or more, preferably 0.0005% by mass or more, still more preferably 0. It is .005% by mass or more, more preferably 0.01% by mass or more. The upper limit of the content of the silver compound is not particularly limited, and examples thereof include 0.2% by mass or less, 0.1% by mass or less, and 0.05% by mass or less.
また、本発明の抗アレルゲン剤の原液において、銀化合物の含有率については、水等の液性媒体で希釈して本発明の抗アレルゲン剤を調製できれば特に制限されず、例えば、例えば０．００１５質量％以上、好ましくは０．００３質量％以上、さらに好ましくは０．００６質量％以上、さらに好ましくは０．０１２質量％以上である。なお、原液における銀化合物の含有率の上限については、特に制限はなく、例えば、１質量％以下、０．５質量％以下、０．１質量％以下などが挙げられる。 Further, the content of the silver compound in the stock solution of the anti-allergen agent of the present invention is not particularly limited as long as it can be diluted with a liquid medium such as water to prepare the anti-allergen agent of the present invention, for example, 0.0015. By mass or more, preferably 0.003% by mass or more, more preferably 0.006% by mass or more, still more preferably 0.012% by mass or more. The upper limit of the content of the silver compound in the undiluted solution is not particularly limited, and examples thereof include 1% by mass or less, 0.5% by mass or less, and 0.1% by mass or less.
また、銅化合物としては、本発明の効果を奏することを限度として、特に制限されず、具体例としては、硝酸銅、酸化銅、硫化銅、硫酸銅、塩化銅などが挙げられる。これらの中でも、水への溶解度が高いことから、硝酸銅が好ましい。本発明の抗アレルゲン剤に含まれる銅化合物は、１種類のみであってもよいし、２種類以上であってもよい。 The copper compound is not particularly limited as long as the effect of the present invention is exhibited, and specific examples thereof include copper nitrate, copper oxide, copper sulfide, copper sulfate, and copper chloride. Among these, copper nitrate is preferable because of its high solubility in water. The copper compound contained in the anti-allergen agent of the present invention may be only one kind or two or more kinds.
本発明の抗アレルゲン剤において、銅化合物の割合は、リン酸チタニウム系化合物を１００質量部として、好ましくは０～８００質量部、より好ましくは１～４００質量部、さらに好ましくは１０～２００質量部である。 In the anti-allergen agent of the present invention, the ratio of the copper compound is preferably 0 to 800 parts by mass, more preferably 1 to 400 parts by mass, still more preferably 10 to 200 parts by mass, with 100 parts by mass of the titanium phosphate compound. Is.
本発明の抗アレルゲン剤において、銅化合物の含有率については、本発明の効果を奏すれば特に制限はなく、例えば０．００１質量％以上、好ましくは０．０１質量％以上、さらに好ましくは０．１質量％以上、さらに好ましくは０．３質量％以上である。なお、銅化合物の含有率の上限については、特に制限はなく、例えば、１．２５質量％以下、１．０質量％以下、０．７５質量％以下などが挙げられる。 In the anti-allergen agent of the present invention, the content of the copper compound is not particularly limited as long as the effect of the present invention is exhibited, for example, 0.001% by mass or more, preferably 0.01% by mass or more, and more preferably 0. .1% by mass or more, more preferably 0.3% by mass or more. The upper limit of the content of the copper compound is not particularly limited, and examples thereof include 1.25% by mass or less, 1.0% by mass or less, and 0.75% by mass or less.
また、本発明の抗アレルゲン剤の原液において、銅化合物の含有率については、水等の液性媒体で希釈して本発明の抗アレルゲン剤を調製できれば特に制限されず、例えば、例えば０．０３質量％以上、好ましくは０．１質量％以上、さらに好ましくは０．３質量％以上、さらに好ましくは０．５質量％以上である。なお、原液における銅化合物の含有率の上限については、特に制限はなく、例えば、６質量％以下、４質量％以下、２質量％以下などが挙げられる。 Further, the content of the copper compound in the stock solution of the anti-allergen agent of the present invention is not particularly limited as long as it can be diluted with a liquid medium such as water to prepare the anti-allergen agent of the present invention, for example, 0.03. By mass or more, preferably 0.1% by mass or more, more preferably 0.3% by mass or more, still more preferably 0.5% by mass or more. The upper limit of the content of the copper compound in the undiluted solution is not particularly limited, and examples thereof include 6% by mass or less, 4% by mass or less, and 2% by mass or less.
本発明の抗アレルゲン剤は、リン酸チタニウム系化合物を含む水溶液であることが好ましい。すなわち、本発明の抗アレルゲン剤は、少なくともリン酸チタニウム系化合物と水を含むことが好ましい。本発明の抗アレルゲン剤において、水の含有率としては、特に制限されず、例えば５０質量％以上、好ましくは７０質量％以上、さらに好ましくは９０質量％以上、さらに好ましくは９５質量％以上である。なお、水の含有率の上限については、特に制限はなく、例えば、９９．９質量％以下、９９.５質量％以下、９９質量％以下などが挙げられる。 The anti-allergen agent of the present invention is preferably an aqueous solution containing a titanium phosphate-based compound. That is, the anti-allergen agent of the present invention preferably contains at least a titanium phosphate-based compound and water. In the anti-allergen agent of the present invention, the water content is not particularly limited, and is, for example, 50% by mass or more, preferably 70% by mass or more, more preferably 90% by mass or more, still more preferably 95% by mass or more. .. The upper limit of the water content is not particularly limited, and examples thereof include 99.9% by mass or less, 99.5% by mass or less, and 99% by mass or less.
本発明の抗アレルゲン剤には、必要に応じて添加剤（前述したリン酸チタニウム系化合物、ケイ酸化合物、銀化合物、及び銅化合物とは異なる成分）が含まれてもよい。添加剤としては、任意の担体、基剤、溶剤、分散剤、乳化剤、緩衝剤、キレート剤、安定化剤、賦形剤、結合剤、崩壊剤、滑沢剤、増粘剤、保湿剤、着色料、香料、媒体などが挙げられる。 The anti-allergen agent of the present invention may contain an additive (a component different from the above-mentioned titanium phosphate compound, silicic acid compound, silver compound, and copper compound), if necessary. Additives include any carrier, base, solvent, dispersant, emulsifier, buffer, chelating agent, stabilizer, excipient, binder, disintegrant, lubricant, thickener, moisturizer, etc. Colorants, fragrances, media and the like can be mentioned.
本発明の抗アレルゲン剤における添加剤の含有率については、本発明の効果を阻害しないことを限度として、その添加目的に応じて適宜調整すればよい。 The content of the additive in the anti-allergen agent of the present invention may be appropriately adjusted according to the purpose of addition thereof, as long as the effect of the present invention is not impaired.
また、本発明の抗アレルゲン剤を製造する際には、水、アルコールなどの液性媒体を使用することが好ましく、これらの液性媒体を使用した場合、本発明の抗アレルゲン剤には、当該液性媒体も含有される。液性媒体としては、水の他、アルコールなどが例示される。アルコールの具体例としては、Ｃ１－４アルコール（エタノール、メタノール、ｎ－プロピルアルコール、イソプロピルアルコール、ｎ－ブチルアルコール、イソブチルアルコール、ｓｅｃ－ブチルアルコール、ｔｅｒｔ－ブチルアルコール）等を挙げることができる。これらのアルコールの中でも、エタノール、イソプロピルアルコールなどが好ましい。 Further, when producing the anti-allergen agent of the present invention, it is preferable to use a liquid medium such as water or alcohol, and when these liquid media are used, the anti-allergen agent of the present invention is said to be the same. A liquid medium is also included. Examples of the liquid medium include alcohol and the like in addition to water. Specific examples of the alcohol include C1-4 alcohol (ethanol, methanol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutyl alcohol, sec-butyl alcohol, tert-butyl alcohol) and the like. Among these alcohols, ethanol, isopropyl alcohol and the like are preferable.
本発明の抗アレルゲン剤は、透明であることが好ましく、無色透明であることがさらに好ましい。また、本発明の抗アレルゲン剤のｐＨは、例えば１～９程度である。 The anti-allergen agent of the present invention is preferably transparent, and more preferably colorless and transparent. The pH of the anti-allergen agent of the present invention is, for example, about 1 to 9.
本発明の抗アレルゲン剤が対象とするアレルゲンとしては、特に制限されないが、スギ花粉由来のアレルゲン、ヒノキ花粉由来のアレルゲン等の植物性蛋白、ダニ（ダニ虫体やその排泄物）由来のアレルゲン等の動物性蛋白などが挙げられ、本発明の抗アレルゲン剤は、スギ花粉由来のアレルゲン及びダニ由来のアレルゲンに対して特に有効である。 The allergen targeted by the anti-allergen agent of the present invention is not particularly limited, but is limited to allergens derived from cedar pollen, plant proteins such as allergens derived from hinoki pollen, allergens derived from ticks (mite worms and their excreta), and the like. The anti-allergen agent of the present invention is particularly effective against allergens derived from cedar pollen and allergens derived from ticks.
本発明の抗アレルゲン剤の使用形態としては、抗アレルゲン剤がアレルゲンと接触、反応して、アレルゲンを不活性化させることができれば特に制限されない。例えば、本発明の抗アレルゲン剤を、対象物の表面に付着させる使用形態が好ましい。本発明の抗アレルゲン剤が付着した対象物の表面に、アレルゲンが付着すると、抗アレルゲン剤とアレルゲンとが反応してアレルゲンを不活性化させることができる。これにより、対象物に対して、抗アレルゲン性能を付与することができる。 The form of use of the anti-allergen agent of the present invention is not particularly limited as long as the anti-allergen agent can contact and react with the allergen to inactivate the allergen. For example, a usage mode in which the anti-allergen agent of the present invention is attached to the surface of an object is preferable. When the allergen adheres to the surface of the object to which the anti-allergen agent of the present invention is attached, the anti-allergen agent and the allergen can react with each other to inactivate the allergen. This makes it possible to impart anti-allergen performance to the object.
前記の通り、本発明の抗アレルゲン剤は、製造・保管・流通させる際には原液の形態とし、用時に水等の液性媒体で希釈して抗アレルゲン剤とし、対象物に付着させて抗アレルゲン性能を付与することもできる。原液の希釈倍率としては、原液から抗アレルゲン剤が好適に製造されれば特に制限されず、例えば１０～５０倍とすればよい。 As described above, the anti-allergen agent of the present invention is in the form of a stock solution when manufactured, stored and distributed, diluted with a liquid medium such as water at the time of use to obtain an anti-allergen agent, and adhered to an object to prevent it. It is also possible to impart allergen performance. The dilution ratio of the undiluted solution is not particularly limited as long as the anti-allergen agent is suitably produced from the undiluted solution, and may be, for example, 10 to 50 times.
本発明の抗アレルゲン剤を、対象物の表面に付着させる方法としては、特に制限されず、例えば、抗アレルゲン剤を対象物に噴霧する方法が挙げられる。これにより、対象物の表面に抗アレルゲン剤を好適に付着させることができる。 The method for adhering the anti-allergen agent of the present invention to the surface of the object is not particularly limited, and examples thereof include a method of spraying the anti-allergen agent on the object. As a result, the anti-allergen agent can be suitably attached to the surface of the object.
本発明の抗アレルゲン剤を付着させる対象物としては、特に制限されない。対象物の具体例としては、ＯＡ機器、家電、空調機器、掃除機、机、椅子、ソファー、ベンチ、窓、壁、床、天井、つり革、ハンドル、シート、自動改札機、自動券売機、自動販売機、扉、柵、手摺、食器、調理用具、包装フィルム、包装袋、瓶、ボトル、包装パック、シンク、便器、文房具、書籍、棚、歯ブラシ、鏡、空調フィルター、マスク、コート、ジャケット、ズボン、スカート、病衣、白衣、手術衣、ワイシャツ、ニットシャツ、ブラウス、セーター、カーディガン、ナイトウエア、肌着、下着、オムツ、サポーター、靴下、タイツ、ストッキング、帽子、スカーフ、マフラー、襟巻き、ストール、手袋、服の裏地、服の芯地、服の中綿、作業着、ユニフォーム、学童用制服等の衣料、カーテン、アミ戸、布団地、布団綿、布団カバー、枕カバー、シーツ、マット、カーペット、タオル、ハンカチ、壁布、絆創膏、包帯等が挙げられる。 The object to which the anti-allergen agent of the present invention is attached is not particularly limited. Specific examples of objects include OA equipment, home appliances, air conditioning equipment, vacuum cleaners, desks, chairs, sofas, benches, windows, walls, floors, ceilings, leather, handles, seats, automatic ticket gates, automatic ticket vending machines, etc. Vending machines, doors, fences, handrails, tableware, cooking utensils, packaging films, packaging bags, bottles, bottles, packaging packs, sinks, toilet bowls, stationery, books, shelves, toothbrushes, mirrors, air conditioning filters, masks, coats, jackets. , Trousers, skirts, sick clothes, white clothes, surgical clothes, shirts, knit shirts, blouses, sweaters, cardigans, nightwear, underwear, underwear, omelets, supporters, socks, tights, stockings, hats, scarves, mufflers, scarves, Stalls, gloves, clothes linings, clothes cores, clothes batting, work clothes, uniforms, school uniforms and other clothing, curtains, scarves, scarves, cloth cotton, cloth covers, pillowcases, sheets, mats, Examples include carpets, towels, handkerchiefs, wall cloths, adhesive plasters, bandages and the like.
本発明の抗アレルゲン剤の使用量は、使用対象、使用目的、及び使用環境等によって適宜調整する。例えば、本発明の抗アレルゲン剤を壁に対して適用するのであれば、抗アレルゲン剤の使用量は、例えば１５～２０ｃｃ／ｍ2程度とすることができる。また、抗アレルゲン剤を使用する際の温度としては、通常は室温（例えば０～４５℃の範囲）である。 The amount of the anti-allergen agent of the present invention to be used is appropriately adjusted according to the target of use, the purpose of use, the environment of use and the like. For example, if the anti-allergen agent of the present invention is applied to a wall, the amount of the anti-allergen agent used can be, for example, about 15 to 20 cc / m 2 . The temperature at which the anti-allergen agent is used is usually room temperature (for example, in the range of 0 to 45 ° C.).
本発明の抗アレルゲン剤は、例えば四塩化チタンの加水分解物を含有する液に、必要に応じて、ケイ酸化合物、銅化合物、及び銀化合物を、この順で混合することにより、好適に製造することができる。この製造方法を採用することにより、抗アレルゲン剤中に沈殿物が殆ど生じず、透明な抗アレルゲン剤を製造することができる。このため、例えば、本発明の抗アレルゲン剤を噴霧して使用する際に、噴霧器に目詰まりが発生することを防止できる等の利点がある。四塩化チタンの加水分解物については、前記の通りである。 The anti-allergen agent of the present invention is suitably produced by mixing, for example, a solution containing a hydrolyzate of titanium tetrachloride with a silicic acid compound, a copper compound, and a silver compound in this order, if necessary. can do. By adopting this production method, a transparent anti-allergen agent can be produced with almost no precipitate formed in the anti-allergen agent. Therefore, for example, when the anti-allergen agent of the present invention is sprayed and used, there is an advantage that clogging can be prevented from occurring in the nebulizer. The hydrolyzate of titanium tetrachloride is as described above.
本発明の抗アレルゲン剤を製造する際の温度は、特に制限されず、通常は室温（例えば０～４５℃の範囲）である。本発明の抗アレルゲン剤を製造する際、各成分を混合、撹拌することが好ましい。抗ウイルス剤に沈殿物が存在する場合には、公知の固液分離工程に供して、斯かる沈殿物を除去してもよい。 The temperature at which the anti-allergen agent of the present invention is produced is not particularly limited, and is usually room temperature (for example, in the range of 0 to 45 ° C.). When producing the anti-allergen agent of the present invention, it is preferable to mix and stir each component. If a precipitate is present in the antiviral agent, it may be subjected to a known solid-liquid separation step to remove the precipitate.
以下に実施例及び比較例を示して本発明を詳細に説明する。但し本発明は実施例に限定されるものではない。 Hereinafter, the present invention will be described in detail with reference to Examples and Comparative Examples. However, the present invention is not limited to the examples.
＜実施例１＞
イソプロピルアルコール２５ｍｌと精製水２５ｍｌの混合溶液に、室温で攪拌しながら四塩化チタン５ｍｌを混合して反応させ、この反応溶液を精製水で１００倍に希釈した。次に、これに８５質量％濃度のリン酸水溶液５ｍｌを加えて反応させることによって、リン酸チタニウム系化合物の溶液を得た。得られたリン酸チタニウム系化合物は、分析の結果、Ｔｉ（ＯＨ）x（ＰＯ4）y（ＨＰＯ4）z（Ｈ2ＰＯ4）l（ＯＲ）m（ここで、Ｒは炭素数１～４のアルキル基を示し、ｘは０～３の整数であり、ｙは０～４の整数であり、ｚは０～４の整数であり、ｌは０～４の整数であり、ｍは０～３の整数であり、ｘ＋３ｙ＋２ｚ＋ｌ＋ｍ＝４であり、ｙ＋ｚ＋１≧１である。）の化学組成又はこれが縮合した化学組成であることを確認した。得られたリン酸チタニウム系化合物の溶液を、さらに精製水で１０倍に希釈して、実施例１の０．２質量％リン酸チタニウム系化合物を含む抗アレルゲン剤とした。実施例１の抗アレルゲン剤は、無色透明な水溶液であった。
<Example 1>
A mixed solution of 25 ml of isopropyl alcohol and 25 ml of purified water was mixed with 5 ml of titanium tetrachloride while stirring at room temperature for reaction, and this reaction solution was diluted 100-fold with purified water. Next, 5 ml of an aqueous solution of phosphoric acid having a concentration of 85% by mass was added thereto and reacted to obtain a solution of a titanium phosphate-based compound. As a result of analysis, the obtained titanium phosphate-based compound was found to be Ti (OH) x (PO 4 ) y (HPO 4 ) z (H 2 PO 4 ) l (OR) m (where R has 1 to 1 carbon atoms). Indicates an alkyl group of 4, x is an integer of 0 to 3, y is an integer of 0 to 4, z is an integer of 0 to 4, l is an integer of 0 to 4, and m is 0. It was confirmed that it is an integer of 3 to 3, x + 3y + 2z + l + m = 4, and y + z + 1 ≧ 1) or a condensed chemical composition. The obtained solution of the titanium phosphate-based compound was further diluted 10-fold with purified water to obtain an anti-allergen agent containing the 0.2% by mass of the titanium phosphate-based compound of Example 1. The anti-allergen agent of Example 1 was a colorless and transparent aqueous solution.
＜実施例２＞
実施例１で得た「リン酸チタニウム系化合物の溶液」に対して、０．１１ｇのケイ酸ナトリウム、３ｇの硝酸銀、及び９０ｇの硝酸銅をこの順で添加し、室温にて混合することによって、０．２質量％リン酸チタニウム系化合物、０．０２質量％ケイ酸ナトリウム、０．００５５質量％硝酸銀、及び０．１６質量％硝酸銅の混合溶液を製造した。得られたリン酸チタニウム系化合物の溶液を、さらに精製水で３０倍に希釈して、実施例２の抗アレルゲン剤とした。実施例２の抗アレルゲン剤は、無色透明な水溶液であった。
<Example 2>
To the "solution of the titanium phosphate compound" obtained in Example 1, 0.11 g of sodium silicate, 3 g of silver nitrate, and 90 g of copper nitrate were added in this order and mixed at room temperature. , 0.2% by mass of Titanium Phosphate compound, 0.02% by mass of sodium silicate, 0.0055% by mass of silver nitrate, and 0.16% by mass of copper nitrate. The obtained titanium phosphate-based compound solution was further diluted 30-fold with purified water to obtain an anti-allergen agent of Example 2. The anti-allergen agent of Example 2 was a colorless and transparent aqueous solution.
［スギ花粉アレルゲン低減効果の評価］
実施例１，２で得られた各抗アレルゲン剤について、それぞれ、スギ花粉アレルゲンの低減効果を評価した。抗アレルゲン剤とアレルゲン溶液を混合し、室温で所定時間反応させた。反応後、混合液を回収し、アレルゲン濃度をＥＬＩＳＡ法にて測定した。対照は抗アレルゲン剤の代わりに精製水を加えること以外は同様に処理した。具体的な試験条件及び評価方法は、それぞれ、以下の通りである。
[Evaluation of Sugi pollen allergen reduction effect]
For each of the anti-allergen agents obtained in Examples 1 and 2, the reducing effect of Sugi pollen allergen was evaluated. The anti-allergen agent and the allergen solution were mixed and reacted at room temperature for a predetermined time. After the reaction, the mixed solution was recovered and the allergen concentration was measured by the ELISA method. Controls were treated similarly except that purified water was added instead of the anti-allergen agent. The specific test conditions and evaluation methods are as follows.
（試験条件）
対象アレルゲン：Ｃｒｙ ｊ １ スギ花粉アレルゲン
対象アレルゲン形態：スギ花粉抽出物（製品Ｎｏ．１０１０３、ＩＴＥＡ製）
アレルゲン初期量：１００ｎｇ
試験温度：室温（空調機を２５℃に設定）
サンプリング数：ｎ＝３
反応時間：５分間または１０分間
アレルゲン測定：サンドウィッチＥＬＩＳＡ
サンドウィッチＥＬＩＳＡにおいては、反応後のアレルゲン溶液をＥＬＩＳＡ測定用希釈液で適切な倍率（被験物である抗アレルゲン剤由来成分がＥＬＩＳＡ測定系に干渉しない希釈倍率であり、添加回収試験により決定）に希釈したものを測定サンプルとし、試験に合わせて最適化した「ＩＴＥＡ スギ花粉アレルゲン（Ｃｒｙ ｊ １）ＥＬＩＳＡキット（製品Ｎｏ．１０２０４、ＩＴＥＡ製）」を用いて測定を行った。
(Test condition)
Target allergen: Cry j 1 Sugi pollen allergen Target allergen Form: Sugi pollen extract (Product No. 10103, manufactured by ITEA)
Initial amount of allergen: 100 ng
Test temperature: Room temperature (air conditioner set to 25 ° C)
Number of samplings: n = 3
Reaction time: 5 minutes or 10 minutes Allergen measurement: Sandwich ELISA
In the sandwich ELISA, the allergen solution after the reaction is diluted with a diluted solution for ELISA measurement to an appropriate magnification (a dilution ratio at which the component derived from the anti-allergen agent as a subject does not interfere with the ELISA measurement system, which is determined by the addition recovery test). The measured sample was used as a measurement sample, and measurement was performed using an "ITEA cedar pollen allergen (Cry j 1) ELISA kit (Product No. 10204, manufactured by ITEA)" optimized for the test.
（評価方法）
以下の数式により、抗アレルゲン剤によるアレルゲン低減率を算出した。
アレルゲン低減率（％）＝（Ｙ－Ｘ）／Ｙ×１００
Ｘ：抗アレルゲン剤と反応後のアレルゲン量平均値（ｎｇ）
Ｙ：対照と反応後のアレルゲン量平均値（ｎｇ）
(Evaluation methods)
The allergen reduction rate by the anti-allergen agent was calculated by the following formula.
Allergen reduction rate (%) = (YX) / Y × 100
X: Average amount of allergen after reaction with anti-allergen agent (ng)
Y: Mean value of allergen amount (ng) after reaction with control
実施例１の抗アレルゲン剤について、５分間反応後のスギ花粉由来アレルゲン（Ｃｒｙ ｊ １）量及びアレルゲン低減率（アレルゲン初期量実測値は１０９．２０ｎｇ）を下表１に示す。 For the anti-allergen agent of Example 1, the amount of sugi pollen-derived allergen (Cry j 1) and the allergen reduction rate (measured value of the initial allergen amount is 109.20 ng) after the reaction for 5 minutes are shown in Table 1 below.
実施例１の抗アレルゲン剤について、１０分間反応後のスギ花粉由来アレルゲン（Ｃｒｙ ｊ １）量及びアレルゲン低減率（アレルゲン初期量実測値は１０２．４２ｎｇ）を下表２に示す。 Table 2 below shows the amount of sugi pollen-derived allergen (Cry j 1) and the allergen reduction rate (measured value of initial allergen amount is 102.42 ng) after the reaction for 10 minutes for the anti-allergen agent of Example 1.
＊１ 検出限界未満 * 1 Below the detection limit
実施例２の抗アレルゲン剤について、５分間反応後のスギ花粉由来アレルゲン（Ｃｒｙ ｊ １）量及びアレルゲン低減率（アレルゲン初期量実測値は９２．８８ｎｇ）を下表３に示す。 For the anti-allergen agent of Example 2, the amount of sugi pollen-derived allergen (Cry j 1) and the allergen reduction rate (measured value of initial allergen amount is 92.88 ng) after the reaction for 5 minutes are shown in Table 3 below.
実施例２の抗アレルゲン剤について、１０分間反応後のスギ花粉由来アレルゲン（Ｃｒｙ ｊ １）量及びアレルゲン低減率（アレルゲン初期量実測値は８８．１０ｎｇ）を下表４に示す。 For the anti-allergen agent of Example 2, the amount of sugi pollen-derived allergen (Cry j 1) and the allergen reduction rate (measured value of the initial allergen amount is 88.10 ng) after the reaction for 10 minutes are shown in Table 4 below.
＊１ 検出限界未満 * 1 Below the detection limit
［ヒノキ花粉アレルゲン低減効果の評価］
実施例２で得られた抗アレルゲン剤について、ヒノキ花粉アレルゲンの低減効果を評価した。抗アレルゲン剤とアレルゲン溶液を混合し、室温で所定時間反応させた。反応後、混合液を回収し、アレルゲン濃度をＥＬＩＳＡ法にて測定した。対照は抗アレルゲン剤の代わりに精製水を加えること以外は同様に処理した。具体的な試験条件及び評価方法は、それぞれ、以下の通りである。
[Evaluation of cypress pollen allergen reduction effect]
The anti-allergen agent obtained in Example 2 was evaluated for its reducing effect on cypress pollen allergen. The anti-allergen agent and the allergen solution were mixed and reacted at room temperature for a predetermined time. After the reaction, the mixed solution was recovered and the allergen concentration was measured by the ELISA method. Controls were treated similarly except that purified water was added instead of the anti-allergen agent. The specific test conditions and evaluation methods are as follows.
（試験条件）
対象アレルゲン：Ｃｈａ ｏ １ ヒノキ花粉アレルゲン
対象アレルゲン形態：ヒノキ花粉抽出物（特注品、ＩＴＥＡ製）
アレルゲン初期量：２１８４６．９２ｎｇ
試験温度：室温（空調機を２５℃に設定）
サンプリング数：ｎ＝３
反応時間：５分間または１０分間
アレルゲン測定：サンドウィッチＥＬＩＳＡ
サンドウィッチＥＬＩＳＡにおいては、反応後のアレルゲン溶液をＥＬＩＳＡ測定用希釈液で適切な倍率（被験物である抗アレルゲン剤由来成分がＥＬＩＳＡ測定系に干渉しない希釈倍率であり、添加回収試験により決定）に希釈したものを測定サンプルとし、試験に合わせて最適化した「ヒノキ花粉アレルゲン（Ｃｈａ ｏ １）ＥＬＩＳＡキット（製品Ｎｏ．４９５００－１９、ニチニチ製薬株式会社）」を用いて測定を行った。
(Test condition)
Target allergen: Cha o 1 Hinoki pollen allergen Target allergen Form: Japanese cypress pollen extract (custom product, made by ITEA)
Initial amount of allergen: 21846.92ng
Test temperature: Room temperature (air conditioner set to 25 ° C)
Number of samplings: n = 3
Reaction time: 5 minutes or 10 minutes Allergen measurement: Sandwich ELISA
In the sandwich ELISA, the allergen solution after the reaction is diluted with a diluted solution for ELISA measurement to an appropriate magnification (a dilution ratio at which the component derived from the anti-allergen agent as a subject does not interfere with the ELISA measurement system, which is determined by the addition recovery test). The measured sample was used as a measurement sample, and measurement was performed using an "Hinoki pollen allergen (Chao 1) ELISA kit (Product No. 49500-19, Nichinichi Pharmaceutical Co., Ltd.)" optimized for the test.
（評価方法）
以下の数式により、抗アレルゲン剤によるアレルゲン低減率を算出した。
アレルゲン低減率（％）＝（Ｙ－Ｘ）／Ｙ×１００
Ｘ：抗アレルゲン剤と反応後のアレルゲン量平均値（ｎｇ）
Ｙ：対照と反応後のアレルゲン量平均値（ｎｇ）
(Evaluation methods)
The allergen reduction rate by the anti-allergen agent was calculated by the following formula.
Allergen reduction rate (%) = (YX) / Y × 100
X: Average amount of allergen after reaction with anti-allergen agent (ng)
Y: Mean value of allergen amount (ng) after reaction with control
実施例２の抗アレルゲン剤について、５分間反応後のヒノキ花粉由来アレルゲン（Ｃｈａ ｏ １）量及びアレルゲン低減率（アレルゲン初期量実測値は２１８４６．９２ｎｇ）を下表５に示す。 For the anti-allergen agent of Example 2, the amount of cypress pollen-derived allergen (Cha o 1) and the allergen reduction rate (allergen initial amount actually measured is 21846.92 ng) after the reaction for 5 minutes are shown in Table 5 below.
実施例２の抗アレルゲン剤について、１０分間反応後のヒノキ花粉由来アレルゲン（Ｃｈａ ｏ １）量及びアレルゲン低減率（アレルゲン初期量実測値は２１８１２．０７ｎｇ）を下表６に示す。 Table 6 below shows the amount of cypress pollen-derived allergen (Cha o 1) and the allergen reduction rate (measured value of initial allergen amount is 21812.07 ng) after the reaction for 10 minutes for the anti-allergen agent of Example 2.
［ダニ虫体アレルゲン低減効果の評価］
実施例２で得られた抗アレルゲン剤について、ダニ虫体アレルゲンの低減効果を評価した。抗アレルゲン剤とアレルゲン溶液を混合し、室温で所定時間反応させた。反応後、混合液を回収し、アレルゲン濃度をＥＬＩＳＡ法にて測定した。対照は抗アレルゲン剤の代わりに精製水を加えること以外は同様に処理した。具体的な試験条件及び評価方法は、それぞれ、以下の通りである。
[Evaluation of mite insect body allergen reduction effect]
The anti-allergen agent obtained in Example 2 was evaluated for its reducing effect on mite insect body allergen. The anti-allergen agent and the allergen solution were mixed and reacted at room temperature for a predetermined time. After the reaction, the mixed solution was recovered and the allergen concentration was measured by the ELISA method. Controls were treated similarly except that purified water was added instead of the anti-allergen agent. The specific test conditions and evaluation methods are as follows.
（試験条件）
対象アレルゲン：Ｄｅｒ ｆ ２ ダニ虫体由来アレルゲン
対象アレルゲン形態：ダニ抽出物（製品Ｎｏ．１０１０２、ＩＴＥＡ製）
アレルゲン初期量：１５０ｎｇ
試験温度：室温（空調機を２５℃に設定）
サンプリング数：ｎ＝３
反応時間：５分間または１０分間
アレルゲン測定：サンドウィッチＥＬＩＳＡ
サンドウィッチＥＬＩＳＡにおいては、反応後のアレルゲン溶液をＥＬＩＳＡ測定用希釈液で適切な倍率（被験物である抗アレルゲン剤由来成分がＥＬＩＳＡ測定系に干渉しない希釈倍率であり、添加回収試験により決定）に希釈したものを測定サンプルとし、試験に合わせて最適化した「ダニアレルゲン（Ｄｅｒ ｆ ２）ＥＬＩＳＡキット（特注品、ＩＴＥＡ製）」を用いて測定を行った。
(Test condition)
Target allergen: Der f 2 Allergen derived from mite insect body Target allergen Form: Tick extract (Product No. 10102, manufactured by ITEA)
Initial amount of allergen: 150 ng
Test temperature: Room temperature (air conditioner set to 25 ° C)
Number of samplings: n = 3
Reaction time: 5 minutes or 10 minutes Allergen measurement: Sandwich ELISA
In the sandwich ELISA, the allergen solution after the reaction is diluted with a diluted solution for ELISA measurement to an appropriate magnification (a dilution ratio at which the component derived from the anti-allergen agent as a subject does not interfere with the ELISA measurement system, which is determined by the addition recovery test). The measured sample was used as a measurement sample, and measurement was performed using a "Dania allergen (Der f 2) ELISA kit (custom-made product, manufactured by ITEA)" optimized for the test.
（評価方法）
以下の数式により、抗アレルゲン剤によるアレルゲン低減率を算出した。
アレルゲン低減率（％）＝（Ｙ－Ｘ）／Ｙ×１００
Ｘ：抗アレルゲン剤と反応後のアレルゲン量平均値（ｎｇ）
Ｙ：対照と反応後のアレルゲン量平均値（ｎｇ）
(Evaluation methods)
The allergen reduction rate by the anti-allergen agent was calculated by the following formula.
Allergen reduction rate (%) = (YX) / Y × 100
X: Average amount of allergen after reaction with anti-allergen agent (ng)
Y: Mean value of allergen amount (ng) after reaction with control
実施例２の抗アレルゲン剤について、５分間反応後のダニ虫体由来アレルゲン（Ｄｅｒ ｆ ２）量及びアレルゲン低減率（アレルゲン初期量実測値は１５０．９３ｎｇ）を下表７に示す。 For the anti-allergen agent of Example 2, the amount of mite worm-derived allergen (Der f 2) and the allergen reduction rate (allergen initial amount actually measured is 150.93 ng) after the reaction for 5 minutes are shown in Table 7 below.
実施例２の抗アレルゲン剤について、１０分間反応後のダニ虫体由来アレルゲン（Ｄｅｒ ｆ ２）量及びアレルゲン低減率（アレルゲン初期量実測値は１５８．３３ｎｇ）を下表８に示す。 For the anti-allergen agent of Example 2, the amount of mite-derived allergen (Der f 2) and the allergen reduction rate (allergen initial amount actually measured is 158.33 ng) after the reaction for 10 minutes are shown in Table 8 below.
［ダニ排泄物アレルゲン低減効果の評価］
実施例２で得られた抗アレルゲン剤について、ダニ排泄物アレルゲンの低減効果を評価した。抗アレルゲン剤とアレルゲン溶液を混合し、室温で所定時間反応させた。反応後、混合液を回収し、アレルゲン濃度をＥＬＩＳＡ法にて測定した。対照は抗アレルゲン剤の代わりに精製水を加えること以外は同様に処理した。具体的な試験条件及び評価方法は、それぞれ、以下の通りである。
[Evaluation of mite excrement allergen reduction effect]
The anti-allergen agent obtained in Example 2 was evaluated for its effect of reducing mite excrement allergen. The anti-allergen agent and the allergen solution were mixed and reacted at room temperature for a predetermined time. After the reaction, the mixed solution was recovered and the allergen concentration was measured by the ELISA method. Controls were treated similarly except that purified water was added instead of the anti-allergen agent. The specific test conditions and evaluation methods are as follows.
（試験条件）
対象アレルゲン：Ｄｅｒ ｆ １ ダニ排泄物由来アレルゲン
対象アレルゲン形態：ダニ抽出物（製品Ｎｏ．１０１０２、ＩＴＥＡ製）
アレルゲン初期量：１５０ｎｇ
試験温度：室温（空調機を２５℃に設定）
サンプリング数：ｎ＝３
反応時間：５分間または１０分間
アレルゲン測定：サンドウィッチＥＬＩＳＡ
サンドウィッチＥＬＩＳＡにおいては、反応後のアレルゲン溶液をＥＬＩＳＡ測定用希釈液で適切な倍率（被験物である抗アレルゲン剤由来成分がＥＬＩＳＡ測定系に干渉しない希釈倍率であり、添加回収試験により決定）に希釈したものを測定サンプルとし、試験に合わせて最適化した「ダニアレルゲン（Ｄｅｒ ｆ １）ＥＬＩＳＡキット（製品Ｎｏ．１０２０５、ＩＴＥＡ製）」を用いて測定を行った。
(Test condition)
Target allergen: Der f 1 Allergen derived from mite excrement Target allergen Form: Tick extract (Product No. 10102, manufactured by ITEA)
Initial amount of allergen: 150 ng
Test temperature: Room temperature (air conditioner set to 25 ° C)
Number of samplings: n = 3
Reaction time: 5 minutes or 10 minutes Allergen measurement: Sandwich ELISA
In the sandwich ELISA, the allergen solution after the reaction is diluted with a diluted solution for ELISA measurement to an appropriate magnification (a dilution ratio at which the component derived from the anti-allergen agent as a subject does not interfere with the ELISA measurement system, which is determined by the addition recovery test). The measured sample was used as a measurement sample, and measurement was performed using a "Dania allergen (Der f 1) ELISA kit (Product No. 10205, manufactured by ITEA)" optimized for the test.
（評価方法）
以下の数式により、抗アレルゲン剤によるアレルゲン低減率を算出した。
アレルゲン低減率（％）＝（Ｙ－Ｘ）／Ｙ×１００
Ｘ：抗アレルゲン剤と反応後のアレルゲン量平均値（ｎｇ）
Ｙ：対照と反応後のアレルゲン量平均値（ｎｇ）
(Evaluation methods)
The allergen reduction rate by the anti-allergen agent was calculated by the following formula.
Allergen reduction rate (%) = (YX) / Y × 100
X: Average amount of allergen after reaction with anti-allergen agent (ng)
Y: Mean value of allergen amount (ng) after reaction with control
実施例２の抗アレルゲン剤について、５分間反応後のダニ排泄物由来アレルゲン（Ｄｅｒ ｆ １）量及びアレルゲン低減率（アレルゲン初期量実測値は１４４．１２ｎｇ）を下表９に示す。 For the anti-allergen agent of Example 2, the amount of mite excrement-derived allergen (Der f 1) and the allergen reduction rate (allergen initial amount actually measured: 144.12 ng) after the reaction for 5 minutes are shown in Table 9 below.
実施例２の抗アレルゲン剤について、１０分間反応後のダニ排泄物由来アレルゲン（Ｄｅｒ ｆ １）量及びアレルゲン低減率（アレルゲン初期量実測値は１４０．０８ｎｇ）を下表１０に示す。 For the anti-allergen agent of Example 2, the amount of mite excrement-derived allergen (Der f 1) and the allergen reduction rate (measured value of initial allergen amount is 140.08 ng) after the reaction for 10 minutes are shown in Table 10 below.
Claims (8)
ケイ酸化合物（但し、ケイ酸マグネシウムを除く）をさらに含む、抗アレルゲン剤。 An anti-allergen agent containing a titanium phosphate compound.
An anti-allergen agent further comprising a silicic acid compound (excluding magnesium silicate).
前記抗アレルゲン剤は、銀化合物及び銅化合物のうち少なくとも一方をさらに含み、
前記銀化合物は、硝酸銀、酸化銀、硫化銀、臭化銀、及びヨウ化銀からなる群より選択される少なくとも１種であり、
前記銅化合物は、硝酸銅、酸化銅、硫化銅、硫酸銅、及び塩化銅からなる群より選択される少なくとも１種である、抗アレルゲン剤。 An anti-allergen agent containing a titanium phosphate compound.
The anti-allergen agent further comprises at least one of a silver compound and a copper compound.
The silver compound is at least one selected from the group consisting of silver nitrate, silver oxide, silver sulfide, silver bromide, and silver iodide.
The copper compound is an anti-allergen agent, which is at least one selected from the group consisting of copper nitrate, copper oxide, copper sulfide, copper sulfate, and copper chloride.
Ｔｉ（ＯＨ）x（ＰＯ4）y（ＨＰＯ4）z（Ｈ2ＰＯ4）l（ＯＲ）m
（Ｒは炭素数１～４のアルキル基を示し、ｘは０～３の整数であり、ｙは０～４の整数であり、ｚは０～４の整数であり、ｌは０～４の整数であり、ｍは０～３の整数であり、ｘ＋３ｙ＋２ｚ＋ｌ＋ｍ＝４であり、ｙ＋ｚ＋１≧１である。） The anti-allergen agent according to any one of claims 1 to 4, wherein the titanium phosphate-based compound is a compound represented by the following general formula and / or a condensate thereof.
Ti (OH) x (PO 4 ) y (HPO 4 ) z (H 2 PO 4 ) l (OR) m
(R represents an alkyl group having 1 to 4 carbon atoms, x is an integer of 0 to 3, y is an integer of 0 to 4, z is an integer of 0 to 4, and l is an integer of 0 to 4. It is an integer, m is an integer of 0 to 3, x + 3y + 2z + l + m = 4, and y + z + 1 ≧ 1.)
請求項１～６のいずれか１項に記載の抗アレルゲン剤を、前記対象物の表面に付着させる、抗アレルゲン性能付与方法。 A method of imparting anti-allergen performance to an object,
A method for imparting anti-allergen performance, wherein the anti-allergen agent according to any one of claims 1 to 6 is attached to the surface of the object.
The method for imparting anti-allergen performance according to claim 7, wherein the anti-allergen agent is adhered to the surface of the object by spraying the anti-allergen agent onto the object.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021117474A JP7039081B1 (en) | 2021-07-15 | 2021-07-15 | Anti-allergen agent and anti-allergen performance imparting method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021117474A JP7039081B1 (en) | 2021-07-15 | 2021-07-15 | Anti-allergen agent and anti-allergen performance imparting method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP7039081B1 true JP7039081B1 (en) | 2022-03-22 |
| JP2023013354A JP2023013354A (en) | 2023-01-26 |
Family
ID=81214279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117474A Active JP7039081B1 (en) | 2021-07-15 | 2021-07-15 | Anti-allergen agent and anti-allergen performance imparting method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7039081B1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3829640B2 (en) | 2001-04-10 | 2006-10-04 | 大阪市 | Antibacterial and antifungal agents and antibacterial or antifungal methods |
| WO2009044648A1 (en) | 2007-10-01 | 2009-04-09 | Toagosei Co., Ltd. | Anti-allergen agent |
| JP4430877B2 (en) | 2003-03-06 | 2010-03-10 | さつき 内田 | Antibacterial and deodorant |
| JP2010235701A (en) | 2009-03-30 | 2010-10-21 | Toagosei Co Ltd | Anti-allergenic composition and anti-allergenic product |
| JP2017075420A (en) | 2015-10-14 | 2017-04-20 | 住化エンバイロメンタルサイエンス株式会社 | Allergen-reducing composition for fiber |
| JP2019099677A (en) | 2017-12-01 | 2019-06-24 | 住化エンバイロメンタルサイエンス株式会社 | Allergen-reducing composition |
| JP2020164604A (en) | 2019-03-28 | 2020-10-08 | 住化エンバイロメンタルサイエンス株式会社 | Allergen-reducing composition |
-
2021
- 2021-07-15 JP JP2021117474A patent/JP7039081B1/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3829640B2 (en) | 2001-04-10 | 2006-10-04 | 大阪市 | Antibacterial and antifungal agents and antibacterial or antifungal methods |
| JP4430877B2 (en) | 2003-03-06 | 2010-03-10 | さつき 内田 | Antibacterial and deodorant |
| WO2009044648A1 (en) | 2007-10-01 | 2009-04-09 | Toagosei Co., Ltd. | Anti-allergen agent |
| JP2012233203A (en) | 2007-10-01 | 2012-11-29 | Toagosei Co Ltd | Anti-allergenic agent |
| JP2010235701A (en) | 2009-03-30 | 2010-10-21 | Toagosei Co Ltd | Anti-allergenic composition and anti-allergenic product |
| JP2017075420A (en) | 2015-10-14 | 2017-04-20 | 住化エンバイロメンタルサイエンス株式会社 | Allergen-reducing composition for fiber |
| JP2019099677A (en) | 2017-12-01 | 2019-06-24 | 住化エンバイロメンタルサイエンス株式会社 | Allergen-reducing composition |
| JP2020164604A (en) | 2019-03-28 | 2020-10-08 | 住化エンバイロメンタルサイエンス株式会社 | Allergen-reducing composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023013354A (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100086617A1 (en) | Antiviral fiber, process for producing the fiber, and textile product comprising the fiber | |
| DE60130332T2 (en) | COMPOSITIONS CONTAINING CYCLODEXTRIN | |
| TW201505639A (en) | Antimicrobial compositions and methods of making the same | |
| JP4157692B2 (en) | Allergen reducing agent | |
| JP3829640B2 (en) | Antibacterial and antifungal agents and antibacterial or antifungal methods | |
| JP7039081B1 (en) | Anti-allergen agent and anti-allergen performance imparting method | |
| JP6820579B2 (en) | Antiviral agents and virus removal methods | |
| CN107683325B (en) | Liquid detergent composition for clothing | |
| JP6735547B2 (en) | Allergen-reducing composition for fibers | |
| JP6509954B2 (en) | Antiviral agent | |
| JP2014500337A (en) | Allergen deactivator composition, article and method | |
| JP6973835B1 (en) | Antiviral agent | |
| JP4825070B2 (en) | Allergen reducing agent | |
| JP2003334240A (en) | Allergen decreasing agent and method for using the same | |
| JP4359126B2 (en) | Water-based allergen inhibitor | |
| JP2004275605A (en) | In door environment improving agent | |
| JP2024087242A (en) | Composition for reducing activity of milk allergen | |
| JP2004346172A (en) | Allergen-diminishing agent | |
| JP2019006898A (en) | Allergen-reducing agent | |
| JP2019194164A (en) | Composition for disinfection | |
| JP5065583B2 (en) | Anti-allergenic surfactant, articles using the same, and textile products for cleaning | |
| JP5510952B2 (en) | Anti-allergen spray composition processed into a mask | |
| CN102978927A (en) | Sweat-proof and wear-resistant antifouling clean-keeping sol and production method thereof | |
| JP2012107253A (en) | Allergen deactivating agent | |
| RU2197086C2 (en) | Agent for domestic dust mites killing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210716 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211019 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220222 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220302 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7039081 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |